Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 7, 2015, Pages 1279-1284

  Furukawa, S ^a   Nogami, K ^a   Ogiwara, K ^a   Yada, K ^a   Minami, H ^a   Shima, M ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood coagulation tests; Factor VIIa; Feiba; Hemophilia A; Hemostasis, surgical; Thromboelastography

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; AUTOANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ELECTIVE SURGERY; HEMOPHILIA A; HEMOSTASIS; HUMAN; PATIENT CARE; PATIENT MONITORING; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTATIONAL THROMBOELASTOMETRY; SCHOOL CHILD; SPIKE; THROMBOELASTOGRAPHY; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; MALE; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AUTOANTIBODIES; BIOMARKERS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; ELECTIVE SURGICAL PROCEDURES; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HEMOSTATICS; HUMANS; MALE; PERIOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; THROMBELASTOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84935736039     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12987     Document Type: Article

References (10)

1. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
2. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478-85.
3. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
4. Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol 2009; 90: 576-82.
5. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia 2008; 14: (Suppl. 4): 20-7.
6. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
7. Young G, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, Pasi J, Ingerslev J. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
8. Sakai M, Taki M, Ieko M, Ida K, Ohira K, Katsunuma T, Takahashi H, Nogami K, Higasa S, Fukutake K, Matsusita I, Matsumoto M, Madoiwa S. Hemostatic treatment guidelines for inhibitors possess congenital hemophilia patients. Jpn J Thromb Hemost 2013; 24: 640-58.
9. Chitlur M, Rivard GE, Lillicrap D, Mann K, Shima M, Young G. Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 103-6.
10. Ogiwara K, Nogami K, Matsumoto T, Shima M. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor. Int J Hematol 2014; 99: 577-87.